With its recent expansion into Illinois and Nevada, Mary's footprint has grown to eight states. The company has plans to expand to an additional three states by mid-2017. In conjunction with the expansion goals, Mary's remains committed to the research and development of cutting-edge products.
"Leading Mary's from an innovative idea in a nascent industry to what it is today—the gold-standard in transdermal cannabis delivery—has been tremendously fulfilling when I think about all of the people we're helping," said Smith. "It's so rewarding to see that as a society we're becoming more open to the possibilities of cannabis. I'm confident Lynn will continue to grow Mary's to the benefit of everyone in this increasingly receptive environment."
Prior to co-founding Mary's, Honderd has previously served in a variety of senior positions with organizations including Bank of America and UBS Paine Webber. Honderd's expertise in financial services and business development has proven invaluable in the quickly evolving cannabis industry, where she has helped to position Mary's Medicinals as the leading producer of pharmaceutical-grade cannabis products in multiple states.
Mary's Medicinals products are currently available in Arizona, California, Colorado, Illinois, Oregon, Nevada, Vermont and Washington. Look for Mary's products in additional states in 2017. Stay up to date on the latest announcements by visiting www.marysmedicinals.com.
About Mary's Medicinals:
Best known as the developer and exclusive distributor of the award-winning transdermal cannabis patch, Mary's Medicinals is a wellness company innovating at the intersection of engineering, technology and horticulture. Mary's mission is to transform how people view and utilize cannabis by developing products that isolate the benefits of cannabinoids and other vital plant extracts for optimum patient care. All Mary's Medicinals products have the Seal of Approval from The Realm of Caring. For more information, please visit www.marysmedicinals.com.
The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficiency of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. If you are taking any medication or are under treatment for any disease, please consult your health care professional about potential interactions or other possible complications before using these products. The Federal Food, Drug and Cosmetic Act requires this notice.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/marys-medicinals-names-lynn-honderd-ceo-300404026.html
SOURCE Mary’s Medicinals